Welcome to our dedicated page for Biotricity SEC filings (Ticker: BTCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biotricity Inc. filings document a Nevada medical technology issuer focused on remote cardiac monitoring, diagnostic and post-diagnostic solutions, and Technology-as-a-Service healthcare workflows. Form 8-K reports include financial-results releases and material definitive agreements tied to the company’s operating updates and capital structure.
The filing record also covers registration-statement disclosures, common stock, warrants, options and preferred-stock terms. Recent capital-structure disclosures include exchange agreements, a certificate of designation for Series C Preferred Stock, voting rights and conversion mechanics, alongside governance and risk information relevant to the company’s public reporting obligations.
Biotricity (BTCY) filed its quarterly report for the period ended September 30, 2025. The company grew revenue to $3,885,795 for the quarter (from $3,266,846) and $7,759,788 for the six months (from $6,468,589). Gross profit rose to $3,181,498 in the quarter, and Biotricity posted operating income of $273,819 compared with a prior-year operating loss. Net loss narrowed to $(690,913) for the quarter and $(1,362,890) year‑to‑date.
Liquidity remains tight with cash of $308,460 and total liabilities of $37,984,860, resulting in a stockholders’ deficit of $(33,412,378). Management disclosed a working capital deficiency of $18,077,790 and stated that these conditions raise substantial doubt about the company’s ability to continue as a going concern. As of November 13, 2025, there were 27,797,711 common shares outstanding, plus 160,672 exchangeable shares, equivalent to 27,958,383 voting securities.